Eversense® E3 Continuous Glucose Monitoring (CGM) System
FDA premarket approval P160048/S022 · decided 2023-03-30
Approval details
- PMA number
- P160048
- Supplement
- S022
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- Eversense® E3 Continuous Glucose Monitoring (CGM) System
- Generic name
- Sensor, glucose, implanted, non-adjunctive use
- Applicant
- Senseonics, Incorporated
- Date received
- 2023-01-31
- Decision date
- 2023-03-30
- Days to decision
- 58 days
- Decision code
- APPR
- Product code
- QHJ
- Advisory committee
- Clinical Chemistry
- Expedited review
- No
- Location
- Germantown, MD
- Statement
- Approval for modifying the Eversense E3 Transmitter, supporting mobile medical application, and the Instructions for Use for consistent use with the modified transmitter.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.
510(k) clearances by this applicant
| Record | Firm | Date |
|---|---|---|
| Eversense 365 Continuous Glucose Monitoring (CGM) System (K241335) | Senseonics, Incorporated | 2024-09-16 |
| Eversense AP CGM System (DEN230052) | Senseonics, Incorporated | 2024-04-29 |